NHS Cancer Programme

The NHS Cancer Programme has published its first quarterly update report, which sets out the programme’s key achievements since April 2019 in delivering the NHS Long Term Plan for cancer, for example: Earlier and faster diagnosis – bowel cancer screening tests, HPV vaccine, Rapid Diagnostic Centres, Faster Diagnosis Standard Personalised care and support – follow-up […]

read more

New first-line treatment option for advanced kidney cancer available on the NHS

Today, the National Institute for Health and Care Excellence (NICE) have recommended tivozanib (Fotivda) as a new first-line treatment option for people with advanced renal cell carcinoma (RCC) for use within NHS England and Wales. This follows a protracted appraisal process involving three committee meetings over 20 months while the process was suspended to allow the manufacturer to submit further […]

read more

Lenvatinib/everolimus combination approved by NICE for use in NHS England and Wales for advanced kidney cancer

Fantastic news for people with advanced kidney cancer: the lenvatinib (Kisplyx) plus everolimus (Afinitor) combination has been recommended by the National Institute for Health and Care Excellence (NICE) for use by the NHS in England and Wales for people with advanced renal cell carcinoma (RCC) that has been previously treated. This is the first combination of treatments to be […]

read more

Call to transform cancer services to improve survival rates in Wales

The following article by the BBC reported that 300 more patients might survive cancer each year in Wales if services were performed to the European average. Tom Crosby, medical director of the Wales Cancer Network, said there needed to be a “relentless drive to diagnose cancers earlier”. Wales has already been on a ‘fact finding’ […]

read more
Showing all 4 results